` BBLG (Bone Biologics Corp) vs S&P 500 Comparison - Alpha Spread

BBLG
vs
S&P 500

Over the past 12 months, BBLG has underperformed S&P 500, delivering a return of -60% compared to the S&P 500's +13% growth.

Stocks Performance
BBLG vs S&P 500

Loading
BBLG
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
BBLG vs S&P 500

Loading
BBLG
S&P 500
Difference
www.alphaspread.com

Performance By Year
BBLG vs S&P 500

Loading
BBLG
S&P 500
Add Stock

Competitors Performance
Bone Biologics Corp vs Peers

S&P 500
BBLG
ABBV
CYTH
AMGN
GILD
Add Stock

Bone Biologics Corp
Glance View

Market Cap
4.8m USD
Industry
Biotechnology

Bone Biologics Corp. operates as a medical device company, which engages in the research and development of bone regeneration in spinal fusion. The company is headquartered in Burlington, Massachusetts and currently employs 2 full-time employees. The company went IPO on 2015-11-27. The firm is also focused on bone regeneration in spinal fusion using the recombinant human protein, known as NELL-1/DBX. The NELL-1/DBX medical device is a combination product which is an osteostimulative recombinant protein that provides target specific control over bone regeneration. The NELL-1/DBX Fusion Device offers a range of procedures including Spine Implants, Non-Union Trauma Cases and Osteoporosis. NELL-1 is a function specific recombinant human protein in laboratory bench models to recapitulate normal human growth and development to provide control over bone and cartilage regeneration. The platform technology is its human protein, known as NELL-1, a skeletal specific growth factor which is a bone void filler. NELL-1 provides regulation over skeletal tissue formation and stem cell differentiation during bone regeneration.

BBLG Intrinsic Value
1.71 USD
Overvaluation 43%
Intrinsic Value
Price
Back to Top